查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2022-2028 年转基因乙型肝炎疫苗市场
市场调查报告书
商品编码
1215769

2022-2028 年转基因乙型肝炎疫苗市场

Recombinant Hepatitis B Vaccine Market 2022-2028
出版日期: | 出版商: Orion Market Research | 英文 | 商品交期: 2-3个工作天内

价格

在预测期内，全球重组乙型肝炎疫苗市场预计将以 5.6% 的复合年增长率显着增长。 市场增长的主要驱动力是由于乙型肝炎流行的加剧，对乙型肝炎疫苗接种和生产的需求激增。 在这个行业经营的公司正专注于与其他市场参与者合作，以扩大业务并保持市场竞争力。 例如，2021 年 5 月，Dynavax Technologies Corp.与 Bavarian Nordic 就在德国销售和分销 HEPLISAV B [乙型肝炎疫苗（重组），佐剂]签订了商业化协议。 HEPLISAV B 是唯一获得美国食品和药物管理局 (FDA) 和欧盟委员会 (EC) 批准的成人乙型肝炎疫苗，允许在一个月内完成两剂方案。 然而，与乙型肝炎疫苗相关的副作用预计会阻碍市场增长。

全球重组乙型肝炎疫苗市场根据类型和应用进行细分。 根据类型，市场分为 10mcg/ml 和 10mcg/0.5ml。 根据应用，市场分为新生儿/儿科和成人。

从地域上看，重组乙型肝炎疫苗市场分为北美、欧洲、亚太地区和世界其他地区。 预计在预测期内，北美将占据最高的市场份额。 由于肝癌上升，对乙型肝炎疫苗的高需求是推动该地区市场增长的一个突出方面。 乙型肝炎疫苗被认为是第一种抗癌疫苗，因为它有助于预防肝癌，肝癌是癌症死亡的第二大原因。 美国癌症协会估计，到 2022 年，美国将诊断出约 41,260 例新病例（28,600 名男性和 12,660 名女性）和 30,520 名（20,420 名男性）原发性肝癌和肝内胆管癌患者（10,100 名女性）死亡来自这些癌症。 这将导致对重组乙型肝炎疫苗的需求增加。

内容

第 1 章报告概述

  • 当前行业分析和增长前景
  • 研究方法和工具
  • 市场细分
    • 按细分
    • 按地区

第 2 章市场概述和洞察

  • 调查范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 推荐
    • 总结

第三章竞争格局

  • 主要公司分析
    • 概览
    • 财务分析
    • SWOT 分析
    • 近期趋势
  • 关键策略分析

第四章市场细分

  • 全球重组乙型肝炎疫苗市场：按类型分类
    • 10微克/毫升
    • 10 微克/0.5 毫升
  • 重组乙型肝炎疫苗的全球应用市场
    • 新生儿/儿科
    • 成人

第五章区域分析

  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 意大利
    • 西班牙
    • 法国
    • 其他欧洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 其他亚太地区
  • 世界其他地方
    • 拉丁美洲
    • 中东和非洲

第六章公司简介

  • Bharat Biotech International Ltd.
  • CSL Ltd.
  • Dynavax Technologies Corp
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline PLC
  • KM Biologics（Meiji Holdings Co., Ltd.）
  • LG Chem Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt., Ltd.
  • Sinovac Biotech Ltd.
  • VBI Vaccines, Inc.
Product Code: OMR2026825

Title:Global Recombinant Hepatitis B Vaccine Market Size, Share and Trends Analysis, By Type (10mcg/ml and 10mcg/0.5ml), By Application (Newborn/ Children and Adult), Forecast Period (2022-2028).

The global recombinant hepatitis B vaccine market is anticipated to grow at a substantial CAGR of 5.6% during the forecast period. The market growth is majorly driven by the growing prevalence of hepatitis B which has surged the demand for hepatitis B vaccination and production on a large level. Companies operating in the industry are focusing on collaborating with other market players to expand their business and remain competitive in the market. For instance, in May 2021, Dynavax Technologies Corp. entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in Germany. HEPLISAV B is the only US Food and Drug Administration (FDA) and European Commission (EC) approved hepatitis B vaccine for adults with a two-dose regimen that is completed in one month. However, the side effects associated with the hepatitis B vaccine are expected to hamper the market growth.

The global recombinant hepatitis B vaccine market is segmented based on type and application. Based on type, the market is bifurcated into 10mcg/ml and 10mcg/0.5ml. Based on application, the market is sub-segmented into newborns/children, and adults.

Geographically, the recombinant hepatitis B vaccine market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to contribute the highest share of the market during the forecast period. The high demand for hepatitis B vaccines due to increasing liver cancer is the prominent aspect driving the regional market growth. The hepatitis B vaccine is the first anti-cancer vaccine because it can help prevent liver cancer, which is the second most common cause of cancer death. As per the American Cancer Society's estimates for primary liver cancer and intrahepatic bile duct cancer in 2022, around 41,260 new cases (28,600 in men and 12,660 in women) will be diagnosed and 30,520 people (20,420 men and 10,100 women) will die of these cancers in the US. That will lead to an increase in demand for recombinant hepatitis B vaccines.

The major market players in the global recombinant hepatitis B vaccine market include Merck & Co., Inc., GlaxoSmithKline plc, Sanofi Pasteur, Dalian Hissen Bio-pharm, and Pfizer Inc., among others. The market players are also contributing significantly to the growth of the market by the adoption of various strategies including mergers and acquisitions, geographical expansion, partnerships, collaborations, and new product launches, to stay competitive in the market. For instance, in January 2021, Dynavax Technologies Corp. announced the final immunogenicity and interim safety results of the ongoing clinical trial evaluating HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] in patients undergoing hemodialysis. As per the company, the hemodialysis trial which reinforces the existing clinical data regarding the safety and ability of HEPLISAV-B provided high rates of protection for patients undergoing hemodialysis.

Research Methodology

The market study of the global recombinant hepatitis B vaccine market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to break down the market into various segments, and derive the total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macroeconomic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of the market size and intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

  • Global Recombinant Hepatitis B Vaccine Research and Analysis by Type
  • Global Recombinant Hepatitis B Vaccine Research and Analysis by Application

The Report Covers:

  • Comprehensive research methodology of the global recombinant hepatitis B vaccine market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global recombinant hepatitis B Vaccine market.
  • Insights about market determinants that are stimulating the global recombinant hepatitis B Vaccine market.
  • Detailed and extensive market segments with the regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
    • 3.1.1. Overview
    • 3.1.2. Financial Analysis
    • 3.1.3. SWOT Analysis
    • 3.1.4. Recent Developments
  • 3.2. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Recombinant Hepatitis B Vaccine Market by Type
    • 4.1.1. 10mcg/ml
    • 4.1.2. 10mcg/0.5ml
  • 4.2. Global Recombinant Hepatitis B Vaccine Market by Application
    • 4.2.1. Newborn/Children
    • 4.2.2. Adult

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East & Africa

6. Company Profiles

  • 6.1. Bharat Biotech International Ltd.
  • 6.2. CSL Ltd.
  • 6.3. Dynavax Technologies Corp
  • 6.4. Emergent BioSolutions Inc.
  • 6.5. GlaxoSmithKline PLC
  • 6.6. KM Biologics (Meiji Holdings Co., Ltd.)
  • 6.7. LG Chem Ltd.
  • 6.8. Merck & Co., Inc.
  • 6.9. Novartis AG
  • 6.10. Pfizer, Inc.
  • 6.11. Sanofi S.A.
  • 6.12. Serum Institute of India Pvt., Ltd.
  • 6.13. Sinovac Biotech Ltd.
  • 6.14. VBI Vaccines, Inc.

LIST OF TABLES

  • 1. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 2. GLOBAL 10MCG/ML RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 3. GLOBAL 10MCG/0.5ML RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 4. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 5. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR NEWBORN/CHILDREN MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 6. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR ADULT MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 7. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
  • 8. NORTH AMERICAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 9. NORTH AMERICAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 10. NORTH AMERICAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 11. EUROPEAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 12. EUROPEAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 13. EUROPEAN RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 14. ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 15. ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 16. ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
  • 17. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
  • 18. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
  • 19. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY TYPE, 2021 VS 2028 (%)
  • 2. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
  • 3. GLOBAL RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 4. GLOBAL 10MCG/ML RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 5. GLOBAL 10MCG/0.5ML RECOMBINANT HEPATITIS B VACCINE MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 6. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR NEWBORN/CHILDREN MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 7. GLOBAL RECOMBINANT HEPATITIS B VACCINE FOR ADULT MARKET SHARE BY REGION, 2021 VS 2028 (%)
  • 8. US RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 9. CANADA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 10. UK RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 11. FRANCE RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 12. GERMANY RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 13. ITALY RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 14. SPAIN RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 15. REST OF EUROPE RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 16. INDIA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 17. CHINA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 18. JAPAN RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 19. SOUTH KOREA RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 20. REST OF ASIA-PACIFIC RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)
  • 21. REST OF THE WORLD RECOMBINANT HEPATITIS B VACCINE MARKET SIZE, 2021-2028 ($ MILLION)